The Long-Term Effect of Weight Loss on the Prevention of Progression to Cirrhosis among Patients with Obesity and MASH-Related F3 Liver Fibrosis
International Journal of Environmental Research and Public Health · 2024
DOI: 10.3390/ijerph21060708 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Environmental Research and Public Health, 2024. Verfasst von Jiafei Niu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic Foundation, Cleveland, OH 44106, USA. Hauptthemen laut MEDLINE: Weight Loss, Liver Cirrhosis, Obesity, Disease Progression. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This multi-center retrospective study examined the effect of weight loss on the prevention of progression to cirrhosis in a sample exclusively composed of patients with obesity and MASH-related F3 liver fibrosis. Adult patients with obesity and biopsy-confirmed MASH-related F3 liver fibrosis (n = 101) from two liver transplant centers in the US were included in the study. A higher proportion of patients who did not progress to cirrhosis achieved >5% weight loss at follow-up (59% vs. 30%, p = 0.045). In multivariable analysis, patients with >5% weight loss at follow-up had a lower hazard of developing cirrhosis compared to patients with no weight loss or weight gain (HR: 0.29, 95%, CI: 0.08–0.96); whereas, diabetes (HR: 3.24, 95%, CI: 1.21–8.67) and higher LDL levels (HR: 1.02, 95%, CI: 1.01–1.04) were associated with higher hazards of progression to cirrhosis. Weight loss >5% has the potential to prevent disease progression to cirrhosis in patients with obesity and MASH-related F3 liver fibrosis. The realization of this benefit requires weight loss maintenance longer than one year. Larger prospective studies are needed to determine how weight loss impacts other patient-centered outcomes such as mortality, hepatic decompensation, and hepatocellular carcinoma in patients with obesity and MASH-related F3 liver fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic Foundation, Cleveland, OH 44106, USA.
- Department of Gastroenterology, St. Joseph Mercy Ann Arbor Hospital, Ypsiilanti, MI 48197, USA.
- Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
- Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44106, USA.
ORCID-Profile: Wael Al-Yaman, Ji Seok Park, Huijun Xiao, James Bena, Omar T Sims
Zitieren
APA
Niu, J., Al-Yaman, W., Pinyopornpanish, K., Park, J. S., Salazar, M., Xiao, H., Bena, J., Lyu, R., Flocco, G., Junna, S. R., Adhami, T., Sims, O. T., & Wakim-Fleming, J. (2024). The Long-Term Effect of Weight Loss on the Prevention of Progression to Cirrhosis among Patients with Obesity and MASH-Related F3 Liver Fibrosis. International Journal of Environmental Research and Public Health. https://doi.org/10.3390/ijerph21060708
Vancouver
Niu J, Al-Yaman W, Pinyopornpanish K, Park JS, Salazar M, Xiao H, et al. The Long-Term Effect of Weight Loss on the Prevention of Progression to Cirrhosis among Patients with Obesity and MASH-Related F3 Liver Fibrosis. International Journal of Environmental Research and Public Health. 2024. doi:10.3390/ijerph21060708
BibTeX
@article{Niu2024,
author = {Niu, Jiafei and Al-Yaman, Wael and Pinyopornpanish, Kanokwan and Park, Ji Seok and Salazar, Miguel and Xiao, Huijun and Bena, James and Lyu, Ruishen and Flocco, Gianina and Junna, Shilpa R and Adhami, Talal and Sims, Omar T and Wakim-Fleming, Jamile},
title = {The Long-Term Effect of Weight Loss on the Prevention of Progression to Cirrhosis among Patients with Obesity and MASH-Related F3 Liver Fibrosis},
journal = {International Journal of Environmental Research and Public Health},
year = {2024},
doi = {10.3390/ijerph21060708}
}
EUVIMED